The estimated Net Worth of Nello Mainolfi is at least $29.9 million dollars as of 1 July 2024. Dr Mainolfi owns over 18,773 units of Kymera Therapeutics stock worth over $29,098,664 and over the last 4 years he sold KYMR stock worth over $0. In addition, he makes $832,619 as Co-Founder, Pres et CEO & Director at Kymera Therapeutics.
Dr has made over 26 trades of the Kymera Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 18,773 units of KYMR stock worth $100,060 on 1 July 2024.
The largest trade he's ever made was exercising 59,732 units of Kymera Therapeutics stock on 17 October 2022 worth over $124,243. On average, Dr trades about 18,772 units every 38 days since 2020. As of 1 July 2024 he still owns at least 649,959 units of Kymera Therapeutics stock.
You can see the complete history of Dr Mainolfi stock trades at the bottom of the page.
Dr. Nello Mainolfi M.D., Ph.D. is the Co-Founder, Pres, CEO & Director at Kymera Therapeutics.
As the Co-Founder, Pres et CEO & Director of Kymera Therapeutics, the total compensation of Dr D at Kymera Therapeutics is $832,619. There are no executives at Kymera Therapeutics getting paid more.
Dr D is 42, he's been the Co-Founder, Pres et CEO & Director of Kymera Therapeutics since . There are 6 older and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics, Inc. is Dr. Jared A. Gollob, 57, who is the Chief Medical Officer.
Nello's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... et Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: